A Comparative Study of Two Tracers in Breast Cancer
Purpose
This study explores the effectiveness of mitoxantrone hydrochloride injection (MHI) compared to technetium-99m (99mTc) for locating sentinel lymph nodes (SLNs) in breast cancer patients. Earlier research showed that MHI is safe and effective, and this study aims to identify any differences that were not previously noted.
Methods
The analysis looked at data from a phase III trial involving breast cancer patients. They received both MHI and 99mTc injections before surgery. Various statistical methods were used to examine differences between the two tracers, considering the influence of having multiple SLNs from the same patient.
Results
A total of 463 SLNs from 109 patients were removed, with 47 being pathologically positive. The detection rates of SLNs were similar for both MHI and 99mTc. However, MHI blue staining was found to be an important indicator of positive results, while the 99mTc signal was not significant.
Conclusion
MHI is as safe as 99mTc and has similar SLN detection rates, but it shows better sensitivity for positive SLNs.
Value of Clinical Trials
Clinical trials play a vital role in developing new treatments. It is essential to apply their findings in daily medical practice. Our AI-driven platform, DocSym, simplifies access to standards and protocols, aiding clinicians in making informed decisions.
Enhancing Healthcare Operations
In today’s healthcare landscape, efficiency is key. Our mobile applications facilitate scheduling, treatment monitoring, and telemedicine, improving patient care management and expanding digital services.
The Benefits of AI in Clinics
By integrating AI, clinics can optimize workflows, enhance patient outcomes, and reduce paperwork. Discover how we can assist you at aidevmd.com.
